Predicting chemotherapy success for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial looks at whether a biopsy taken before chemotherapy can help predict how well the treatment will work for people with esophageal squamous cell carcinoma. It aims to improve future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with esophageal squamous cell carcinoma (a type of throat cancer).
- You have already received chemotherapy for your cancer.
- This was your first round of chemotherapy (not a repeat treatment).
- You have a biopsy sample taken before starting chemotherapy that can be used for testing.
- You do not have any other types of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses stored tumor tissue to try to predict if esophageal cancer will come back early after surgery. It is for people who had surgery only (no chemo or radiation) and have been followed for at least 2 years.
This trial tests combining chemotherapy with immunotherapy before surgery for esophageal squamous cell carcinoma. It aims to see how these treatments change the tumor environment and may increase the chance of successful surgery.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial looks at whether a personalized blood test can detect cancer returning after surgery for esophageal cancer. It tests people who had chemoradiotherapy before surgery and still had some cancer remaining in the removed tissue. The goal is to use the blood test to catch any remaining or returning cancer early.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This Phase 3 study compares two treatment plans before surgery for locally advanced esophageal squamous cell carcinoma. It tests whether adding pembrolizumab (an immune therapy) to chemotherapy improves outcomes compared with standard chemoradiation.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.